• Record H1 FY26 revenue of approximately $17.1 million, up 11% year-on-year
• US Technegas® revenue up 73% year-on-year
• 70 revenue-generating Technegas® primary sites in the US as of 1 July 2026
• US installation guidance deferred to after 31 December 2026
• Closing cash balance of approximately $12.2 million as at 30 June 2026

Cyclopharm Ltd. (ASX: CYC) announced a record first half of FY 2026 (H1 FY26) with global revenue of approximately $17.1 million, up 11% year-on-year. US Technegas® revenue grew approximately 73% to around $2.1 million, reflecting the acceleration in revenue-generating installations since the AGM. The company now has 70 primary US sites generating revenue, up from 50 at the AGM. Despite this momentum, delays in finalizing clinical guidelines have impacted pipeline progression, resulting in the deferral of the short-term guidance target for US installations to after 31 December 2026. The company remains committed to its medium-term target of around 2,000 installations from a current US universe of 5,200 potential sites. The closing cash balance as at 30 June 2026 was approximately $12.2 million. The company has passed peak cash burn, with each new installation generating a recurring consumable revenue stream.

Global revenue of approximately $17.1 million for H1 FY26, up 11% year-on-year

Cyclopharm Ltd. remains confident in achieving its medium-term target of over 2,000 revenue-generating installations in the United States. The company anticipates further growth driven by the publication of the revised international lung imaging guideline.